This suppression, mediated via NF-κB pathway inhibition, mirrors the tolerogenic phenotype induced by IL-10 and dexamethasone, suggesting a potential immunomodulatory role relevant to PD, where LAMP3 is a known genetic risk factor [176]. Here, IL10 is linked to Parkinson disease.